Robert Schaffer is a partner in the law firm of Troutman Sanders LLP and is based in the Firm’s New York office. Bob applies his experience to IP litigation, counseling and management, including patent procurement, strategic planning and transactional advice, for biotechnology and pharmaceutical companies, computer software companies and new media firms. He regularly handles domestic and international patent and trademark portfolios and due diligence studies for clients, including major U.S. corporations, start-ups and high-technology ventures. His cases include ANDA matters, complex U.S. Patent and Trademark Office interferences, reexaminations and reissues, strategies for post-grant proceedings.
Bob’s work in the biotechnology and pharmaceutical fields includes directed evolution of genes and proteins; combinatorial chemistry and rational drug design; nano-technology and microfabricated microfluidic devices; genomics and proteomics inventions; cancer treatments; antibiotics; vaccines and therapies for HIV, malaria, diabetes and other diseases; drugs and treatments for autoimmune, cardiac and neurological disorders; diagnostic and genetically engineered antigens and antibodies; pharmaceutical formulations and drug delivery systems; bioequivalence and biosimilarity of drug therapies; therapeutic and industrial enzymes; personalized medicine; bioinformatics; and drug discovery technologies.
Bob’s work for software clients includes counseling for new business methods, digital rights management, streaming and data compression technologies, content delivery, distributed networking, caching and memory management software, security and encryption technologies, network security and diagnostics, software certificates and digital watermarking, anti-virus software, document management software and graphical user interfaces.
Bob is admitted to practice in New York and Connecticut and before the U.S. Court of Appeals for the Federal Circuit (CAFC). He is a registered patent attorney with the U.S. Patent and Trademark Office.
Strategic planning and litigation for drug companies in ANDA litigation.
CAFC appeals involving human growth hormone and industrial enzymes.
Successfully defended ex parte reexamination of client’s key patents covering branded COPD therapy.
Successfully prosecuted inter partes reexamination of competitor’s patent covering certain engineered hormone compounds.
Successful district court litigations concerning recombinant industrial enzymes; food-grade emulsifiers; lentiviral vectors; genetically engineered antibodies; and phage display technology.
Strategic planning and counseling for drug discovery company based on its high-throughput genetic engineering and bioinformatics technology.
Due diligence for major drug company in its evaluation of a potential target concentrating on therapies for infectious diseases caused by bacteria and fungi.
Due diligence for acquisition of complex patent portfolio covering genetically engineered enzymes in the biofuels area.
Prosecution of pioneering content delivery patents for industry leader in internet streaming solutions.
Counseling and prosecution for early-stage company developing media-hub and content server solutions.
Counseling major financial institution in connection with patents concerning electronic checks and on-line banking transactions.
Drafting and negotiation of software development agreement for major financial institution.
Counseling and patenting strategies for document management software.